Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(45 sites)
United States
002, Fair Oaks, California 001, La Jolla, California 004, Washington D.C., District of Columbia 005, Boston, Massachusetts 009, Santa Fe, New Mexico 011, Chapel Hill, North Carolina 012, Nashville, Tennessee Canada
021, Kelowna, British Columbia China
024, Guangzhou, Guangdong Spain
034, Barcelona, Barcelona 035, Barcelona, Barcelona 038, Moncloa-Aravaca, Madrid 041, Pozuelo de Alarcón, Madrid